Cardiovasc Res 36:276281 Masaki I, Yonemitsu Y, Yamashita A, Sata S, Tanii M, Komori K, Nakagawa K, Hou X, Nagai Y, Hasegawa M et al (2002) Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2
Any suspected adverse drug reaction, including a haemolytic episode in a G6PD-deficient patient, should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk to support ongoing pharmacovigilance
Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
-2.6/2.7 kg), respectively (7274)
Formulated with Dr Bruce Syme BVSc (Hons) IVAS for ALL LIFE STAGES Pack Sizes: 200g